A Trial of SHR-7367 in Subjects With Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-7367
Dose-limiting toxicities (DLTs), Number of participants with DLTs, Up to 3 weeks|Recommended phase II dose, The Recommended phase II dose of SHR-7367 injection, first dose of study medication up to 21 days|Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), • Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Up to 12 months
Tumor response using RECIST 1.1, From first dose to disease progression or death, whichever comes first, up to 12 months|peak time (Tmax), Up to 12 months|peak concentration (Cmax), Up to 12 months|area under curve from 0 to the last measurable concentration time point t (AUC0-t),, Up to 12 months|area under curve from 0 to infinity (AUC0-∞), Up to 12 months|elimination half-life (t1/2), Up to 12 months|clearance rate (CL), Up to 12 months|steady-state apparent volume of distribution (Vss), Up to 12 months|steady-state peak concentration (Cmax, ss), Up to 12 months|steady-state valley concentration (Ctrough, ss), Up to 12 months|accumulation ratio (Rac), Up to 12 months|percentage of activated B lymphocyte subsets in peripheral blood, Up to 12 months|Immunogenicity index: drug-resistant antibody (ADA), Up to 12 months|Efficacy endpoints: Objective response rate (ORR), Up to 12 months
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-7367 in subjects with advanced solid tumors.